Literature DB >> 17761659

Consensus statement for standard of care in spinal muscular atrophy.

Ching H Wang1, Richard S Finkel, Enrico S Bertini, Mary Schroth, Anita Simonds, Brenda Wong, Annie Aloysius, Leslie Morrison, Marion Main, Thomas O Crawford, Anthony Trela.   

Abstract

Spinal muscular atrophy is a neurodegenerative disease that requires multidisciplinary medical care. Recent progress in the understanding of molecular pathogenesis of spinal muscular atrophy and advances in medical technology have not been matched by similar developments in the care for spinal muscular atrophy patients. Variations in medical practice coupled with differences in family resources and values have resulted in variable clinical outcomes that are likely to compromise valid measure of treatment effects during clinical trials. The International Standard of Care Committee for Spinal Muscular Atrophy was formed in 2005, with a goal of establishing practice guidelines for clinical care of these patients. The 12 core committee members worked with more than 60 spinal muscular atrophy experts in the field through conference calls, e-mail communications, a Delphi survey, and 2 in-person meetings to achieve consensus on 5 care areas: diagnostic/new interventions, pulmonary, gastrointestinal/nutrition, orthopedics/rehabilitation, and palliative care. Consensus was achieved on several topics related to common medical problems in spinal muscular atrophy, diagnostic strategies, recommendations for assessment and monitoring, and therapeutic interventions in each care area. A consensus statement was drafted to address the 5 care areas according to 3 functional levels of the patients: nonsitter, sitter, and walker. The committee also identified several medical practices lacking consensus and warranting further investigation. It is the authors' intention that this document be used as a guideline, not as a practice standard for their care. A practice standard for spinal muscular atrophy is urgently needed to help with the multidisciplinary care of these patients.

Entities:  

Mesh:

Year:  2007        PMID: 17761659     DOI: 10.1177/0883073807305788

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  178 in total

1.  Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists.

Authors:  Amy T Waldman; Mark P Gorman; Mary R Rensel; Tracy E Austin; Deborah P Hertz; Nancy L Kuntz
Journal:  J Child Neurol       Date:  2011-04-25       Impact factor: 1.987

Review 2.  Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Jeffrey M Statland; Richard J Barohn; April L McVey; Jonathan S Katz; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 3.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

4.  Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients.

Authors:  Miloš Brkušanin; Ana Kosać; Vladimir Jovanović; Jovan Pešović; Goran Brajušković; Nikola Dimitrijević; Slobodanka Todorović; Stanka Romac; Vedrana Milić Rašić; Dušanka Savić-Pavićević
Journal:  J Hum Genet       Date:  2015-08-27       Impact factor: 3.172

5.  Spinal muscular atrophy: advances in research and consensus on care of patients.

Authors:  Ching H Wang; Mitchell R Lunn
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

6.  Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy.

Authors:  Rachel L Lenhart; Sylvester Youlo; Mary K Schroth; Kenneth J Noonan; James McCarthy; David Mann; Scott Hetzel; Sarah A Sund; Matthew A Halanski
Journal:  J Pediatr Orthop       Date:  2017-12       Impact factor: 2.324

7.  Noninvasive treatment strategy for swallowing problems related to prolonged nonoral feeding in spinal muscular atrophy type II.

Authors:  Tae-Hyun Cha; Duck-Won Oh; Jae-Hun Shim
Journal:  Dysphagia       Date:  2010-01-20       Impact factor: 3.438

8.  The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.

Authors:  Constantin d'Ydewalle; Daniel M Ramos; Noah J Pyles; Shi-Yan Ng; Mariusz Gorz; Celeste M Pilato; Karen Ling; Lingling Kong; Amanda J Ward; Lee L Rubin; Frank Rigo; C Frank Bennett; Charlotte J Sumner
Journal:  Neuron       Date:  2016-12-22       Impact factor: 17.173

9.  The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy type II patients.

Authors:  Shih-Hsiang Chou; Gau-Tyan Lin; Po-Chih Shen; Yi-Jing Lue; Cheng-Chang Lu; Yin-Chun Tien; Yen-Mou Lu
Journal:  Eur Spine J       Date:  2016-11-02       Impact factor: 3.134

10.  Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings.

Authors:  Rebecca Hurst Davis; Barbara J Godshall; Erin Seffrood; Mary Marcus; Bernard A LaSalle; Brenda Wong; Mary K Schroth; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2013-10-04       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.